Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 1, 2006, Pages

  LeBrasseur, Nathan K ^a   Kelly, Meghan ^a   Tsao, Tsu Shuen ^b   Farmer, Stephen R ^a   Saha, Asish K ^a   Ruderman, Neil B ^a   Tomas, Eva ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Acetyl coenzyme A carboxylase; Adiponectin; Diabetes; Insulin sensitivity; Metabolism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DEOXYGLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; P 4120; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; T 2573; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ENERGY; DRUG ACTIVATION; DRUG EFFECT; ENZYME ACTIVATION; EXTENSOR DIGITORUM LONGUS MUSCLE; FATTY ACID OXIDATION; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

ACETYL-COA CARBOXYLASE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; CHROMANS; ENZYME ACTIVATION; FATTY ACIDS; GLUCOSE; HYPOGLYCEMIC AGENTS; MALE; MICE; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SWISS 3T3 CELLS; THIAZOLIDINEDIONES;

EID: 33745869049     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00453.2005     Document Type: Article

References (49)

1. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, and Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327, 1997.
2. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR III, Young LH, and Shulman GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50: 1076-1082, 2001.
3. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, and Willson TM. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48: 1415-1424, 1999.
4. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, and Furnsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. Diabetes 50: 2309-2315, 2001.
5. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, and Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53: 1052-1059, 2004.
6. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, and Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900-2908, 1997.
7. Castelein H, Gulick T, Declercq P, Mannaerts G, Moore D, and Baes M. The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem 269: 26754-26758, 1994.
8. Cha BS, Ciaraldi TP, Park KS, Carter L, Mudaliar SR, and Henry RR. Impaired fatty acid metabolism in type 2 diabetic skeletal muscle is reversed by PPARγ agonists. Am J Physiol Endocrinol Metab 289: E151-E159, 2005.
9. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, and Mathews WR. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286: E252-E260, 2004.
10. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, and Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98: 1004-1009, 1996.
11. Fisher JS, Gao J, Han DH, Holloszy JO, and Nolte LA. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 282: E18-E23, 2002.
12. Frohnert BI, Hui TY, and Bernlohr DA. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 274: 3970-3977, 1999.
13. Fryer LG, Parbu-Patel A, and Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226-25232, 2002.
14. Furnsinn C, Neschen S, Noe C, Bisschop M, Roden M, Vogl C, Schneider B, and Waldhausl W. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Br J Pharmacol 122: 1367-1374, 1997.
15. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, and Chatterjee VK. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 275: 5754-5759, 2000.
16. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, and Ferre P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46: 1393-1399, 1997.
17. Hamm JK, el Jack AK, Pilch PF, and Farmer SR. Role of PPAR gamma in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann NY Acad Sci 892: 134-145, 1999.
18. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, and Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51: 2886-2894, 2002.
19. Kallen CB and Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93: 5793-5796, 1996.
20. Kaushik VK, Young ME, Dean DJ, Kurowski TG, Saha AK, and Ruderman NB. Regulation of fatty acid oxidation and glucose metabolism in rat soleus muscle: effects of AICAR. Am J Physiol Endocrinol Metab 281: E335-E340, 2001.
21. Kim JK, Fillmore JJ, Gavrilova O, Chao L, Higashimori T, Choi H, Kim HJ, Yu C, Chen Y, Qu X, Haluzik M, Reitman ML, and Shulman GI. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52: 1311-1318, 2003.
22. Konrad D, Rudich A, Bilan PJ, Patel N, Richardson C, Witters LA, and Klip A. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48: 954-966, 2005.
23. Kurowski TG, Lin Y, Luo Z, Tsichlis PN, Buse MG, Heydrick SJ, and Ruderman NB. Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle. Diabetes 48: 658-663, 1999.
24. Lee MK and Olefsky JM. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44: 1166-1169, 1995.
25. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956, 1995.
26. Liu J and Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279: 45020-45027, 2004.
27. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
28. Maizels EZ, Ruderman NB, Goodman MN, and Lau D. Effect of acetoacetate on glucose metabolism in the soleus and extensor digitorum longus muscles of the rat. Biochem J 162: 557-568, 1977.
29. McGarry JD and Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14, 1997.
30. Motojima K, Passilly P, Peters JM, Gonzalez FJ, and Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue-and inducer-specific manner. J Biol Chem 273: 16710-16714, 1998.
31. Murase K, Odaka H, Suzuki M, Tayuki N, and Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41: 257-264, 1998.
32. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, and Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281: 2654-2660, 2005.
33. Oliver H and Lowry JVP. A Flexible System of Enzymatic Analysis. New York: Academic, 1972, p. 151-153.
34. Peraldi P, Xu M, and Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100: 1863-1869, 1997.
35. Rosen ED and Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734, 2001.
36. Ruderman N and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3: 340-351, 2004.
37. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, and Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585, 2004.
38. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, and Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585, 2004.
39. Saha AK, Kurowski TG, and Ruderman NB. A malonyl-CoA fuel-sensing mechanism in muscle: effects of insulin, glucose, and denervation. Am J Physiol Endocrinol Metab 269: E283-E289, 1995.
40. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, and Lazar MA. The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001.
41. Tontonoz P, Hu E, Devine J, Beale E, and Spiegelman B. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15: 351-357, 1995.
42. Tsao TS, Murrey HE, Hug C, Lee DH, and Lodish HF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277: 29359-29362, 2002.
43. Vavvas D, Apazidis A, Saha AK, Gamble J, Patel A, Kemp BE, Witters LA, and Ruderman NB. Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. J Biol Chem 272: 13255-13261, 1997.
44. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, and Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276: 25651-25653, 2001.
45. Willson TM, Brown PJ, Sternbach DD, and Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550, 2000.
46. Wong GW, Wang J, Hug C, Tsao TS, and Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 101: 10302-10307, 2004.
47. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, and Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276: 41245-41254, 2001.
48. Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ, and Kraegen EW. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47: 1306-1313, 2004.
49. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, and Nakao K. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50: 1093-1101, 2001.